Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ASP3082 with CYP3A Inhibitors and Inducers in Healthy Adults
NCT07395024Phase 1Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of setidegrasib in solid tumor (3 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Concentration up to 29 days, Area Under the Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration up to 29 days and 4 more. Started Feb 2026; status: active, not recruiting.
02
Drugs
setidegrasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07395024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395024.